A5103029163- Cervical Cancer and HPV Research
- Hepatitis B Virus Studies
- Reproductive tract infections research
- Patient Dignity and Privacy
- Antibiotic Resistance in Bacteria
- Infectious Diseases and Tuberculosis
- Diagnosis and treatment of tuberculosis
- Mycobacterium research and diagnosis
- Orthopedic Infections and Treatments
- Women's cancer prevention and management
- Science and Education Research
- Palliative Care and End-of-Life Issues
- Poxvirus research and outbreaks
- Grief, Bereavement, and Mental Health
- T-cell and Retrovirus Studies
Universidade Federal de Ouro Preto
2020-2025
Globally, cervical cancer is an increasing public health issue, and vaccination against HPV has proven to be effective strategy reduce this neoplasia. The purpose of study was assess the effectiveness quadrivalent vaccine in reducing prevalence incidence infection women, aged 18 24 years old, cities Ouro Preto Mariana, Minas Gerais, Brazil. A concurrent cohort performed, with initial follow-up 12 months. selected young women were interviewed divided into two groups: vaccinated unvaccinated....
Abstract Background Infections with Human Papillomavirus (HPV) are the main cause of cervical cancer. Since 2014, HPV vaccine was introduced in Brazilian National Vaccination Calendar. The purpose this study to assess knowledge adolescent girls and their mothers/guardians about vaccine, identify factors associated knowledge, evaluate immunization dropout rate. Methods This a cross-sectional involving mothers/guardians. Participants underwent an interview that addressed sociodemographic data,...
Dignity therapy (DT) is well established in adult populations, and it likely that could benefit younger people. This study aimed to adapt the Portuguese DT question framework for adolescents (DT-QF-Adol) (ages 10-18).Five stages were followed: (1) DT-QF adults was adapted with original author's collaboration, (2) an expert committee provided feedback on version, (3) initial consensus version of DT-QF-Adol created, (4) consult affirmed final consensus, (5) validation stage a sample 17...